Featured Articles

1. Developing Non-PEG Stabilizer Lipids For Nucleic Acid Lipid Nanoparticles 7/1/2026

   Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.

2. Neoantigen-Based Personalized Cancer Vaccine 7/1/2026

   Personalized cancer vaccines are advancing quickly, but effective delivery remains a major hurdle. Learn how mRNA and lipid nanoparticle design influence targeting, endosomal escape, and repeat dosing.

3. Lipid Nanoparticles For Pulmonary Delivery Of mRNA 7/1/2026

   Gain insight into how nebulized mRNA lipid nanoparticles show preclinical success in lung delivery, offering fresh momentum for inhaled gene therapies targeting respiratory diseases.

4. LNP-Mediated Cell Transfection In Bioreactors Across Workflows 6/24/2026

   Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.

5. Towards A Universal LNP Platform For Multiplex Engineering 6/19/2026

   Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.

6. Extrahepatic Delivery Of mRNA-LNP To Spleen 6/19/2026

   In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.

7. mRNA LNPs Drive Safe, Effective Repeat Dosing In Disease Models 6/19/2026

   Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.

8. A Practical Guide To Autologous CAR T Manufacturing 6/19/2026

   Early process decisions shape scalability, consistency, and compliance in autologous CAR T manufacturing. Learn where variability emerges across the workflow and how to plan ahead.

9. The Invaluable Asset Driving Advanced Therapies Forward 6/19/2026

   Cell therapies are advancing rapidly, but manufacturing delays still limit patient access. Improving operational understanding, reducing risk, and strengthening collaboration may be just as critical.

10. Achieving High CAR T Cell Transduction Using An Automated Platform 6/19/2026

    Automation is reshaping CAR T manufacturing. A modular, closed approach with digital integration supports efficient workflows while maintaining critical functional performance under GMP conditions.